EIDX · Eidos Therapeutics, Inc

-

Please sign in to comment on EIDX

1 Comment

Admin

4 years ago

Eidos Therapeutics, Inc is currently in a long term uptrend where the price is trading 62.6% above its 200 day moving average.

From a valuation standpoint, the stock is 2771.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 38461.1.

Eidos Therapeutics, Inc's total revenue sank by 99.5% to $127K since the same quarter in the previous year.

Its net income has dropped by 535.4% to $-30M since the same quarter in the previous year.

Finally, its free cash flow fell by 355.0% to $-28M since the same quarter in the previous year.

Based on the above factors, Eidos Therapeutics, Inc gets an overall score of 1/5.

CurrencyCode	USD
ISIN	US28249H1041
Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ

Market Cap	5B
PE Ratio	None
Beta	-0.17
Target Price	53.63
Dividend Yield	0.0%

ABOUT

Eidos Therapeutics, Inc

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

EIDX · Eidos Therapeutics, Inc

-

Eidos Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Eidos Therapeutics, Inc using a moving average strategy